Stock events for Soleno Therapeutics, Inc. (SLNO)
Soleno Therapeutics' stock price has been impacted by several key events. The company reported robust Q4 and full-year 2025 financial results, including a significant increase in Q4 net revenue, positive cash flow, and a net income for the full year. VYKAT XR demonstrated strong market adoption. Analysts from H.C. Wainwright and Wells Fargo raised their price targets for SLNO, citing impressive sales figures for VYKAT XR. The stock experienced a decline of 43.17% over the past six months. The stock price declined following a critical report by Scorpion Capital LLC and the company's disclosure of a patient death following DCCR administration. Despite beating Q3 2025 earnings, the stock plunged due to concerns about cooling demand for VYKAT XR.
Demand Seasonality affecting Soleno Therapeutics, Inc.’s stock price
Based on available information, the demand for Soleno Therapeutics' product, VYKAT XR, is not expected to exhibit significant seasonality. Management has indicated a target of approximately 250 new patient starts per quarter, explicitly stating that this excludes the effects of any seasonal factors.
Overview of Soleno Therapeutics, Inc.’s business
Soleno Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases, operating within the Healthcare sector, specifically in the Biotechnology & Medical Research and Pharmaceuticals industry. The company's lead product is Diazoxide Choline Extended-Release tablets (DCCR), marketed as VYKAT XR, a once-daily oral tablet approved by the FDA on March 26, 2025, for the treatment of hyperphagia in patients aged four years and older with Prader-Willi syndrome (PWS). The FDA approval marked a significant transition for the company from a clinical-stage entity to a commercial one, with revenue generation beginning in the second quarter of 2025. DCCR has received Fast-Track designation for PWS and orphan drug designation in both the United States and the European Union.
SLNO’s Geographic footprint
Soleno Therapeutics, Inc. is headquartered in Redwood City, California, United States. The company holds orphan drug designation for its lead product, DCCR, in both the United States and the European Union, indicating its market focus in these regions. The approval of VYKAT XR presents opportunities for Soleno to expand into new markets, both domestically and internationally, leveraging the global demand for rare disease treatments. European expansion is currently advancing, with EU approval for DCCR anticipated in mid-2026.
SLNO Corporate Image Assessment
Soleno Therapeutics' brand reputation has been shaped by both significant achievements and notable challenges. The FDA approval of VYKAT XR and its subsequent commercial launch significantly bolstered the company's credibility. The company's reputation faced considerable challenges due to a critical report published by Scorpion Capital LLC, the disclosure of a patient death after taking DCCR, and a class-action lawsuit filed against Soleno.
Ownership
Soleno Therapeutics, Inc. has a significant concentration of institutional ownership. As of February 26, 2026, institutional ownership was high at 107.14%, while insider ownership was reported at 3.09%. Major institutional owners include Fmr Llc, Janus Henderson Group Plc, and BlackRock, Inc. Key individual owners include Andrew Sinclair, Abingworth LLP, and Edgar Engleman.
